4726 Stock Overview
Develops and manufactures biopharmaceutical products from mammalian and microbial cell lines in Taiwan, Europe, Asia, and the United States. More details
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Mycenax Biotech Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | NT$45.30 |
52 Week High | NT$65.20 |
52 Week Low | NT$34.90 |
Beta | 1.06 |
11 Month Change | -10.12% |
3 Month Change | -15.33% |
1 Year Change | 28.15% |
33 Year Change | 14.54% |
5 Year Change | 100.44% |
Change since IPO | 155.93% |
Recent News & Updates
Shareholder Returns
4726 | TW Biotechs | TW Market | |
---|---|---|---|
7D | -3.8% | -3.1% | -0.8% |
1Y | 28.1% | 2.0% | 29.0% |
Return vs Industry: 4726 exceeded the TW Biotechs industry which returned 2% over the past year.
Return vs Market: 4726 matched the TW Market which returned 29% over the past year.
Price Volatility
4726 volatility | |
---|---|
4726 Average Weekly Movement | 3.9% |
Biotechs Industry Average Movement | 4.5% |
Market Average Movement | 4.5% |
10% most volatile stocks in TW Market | 8.0% |
10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 4726 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 4726's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2001 | 387 | Pei-Jiun Chen | www.mycenax.com.tw |
Mycenax Biotech Inc. develops and manufactures biopharmaceutical products from mammalian and microbial cell lines in Taiwan, Europe, Asia, and the United States. The company develops monoclonal antibodies, bi-specific antibodies, fc-fusion proteins, recombinant proteins, peptides, protein conjugates (non-toxin), antibody-cell conjugates, enzymes, antigen-binding fragments (Fab), and single-chain variable fragments (ScFv), as well as plasmids and DNA vaccines. It also provides process development solutions, including development of production cell lines, upstream and downstream process development, process scale-up, formulation development, and analytical methods; in-house analytical services; GMP manufacturing services, such as drug substance and products manufacturing, and cell banking; and manufacturing technologies.
Mycenax Biotech Inc. Fundamentals Summary
4726 fundamental statistics | |
---|---|
Market cap | NT$9.34b |
Earnings (TTM) | -NT$536.33m |
Revenue (TTM) | NT$672.85m |
13.9x
P/S Ratio-17.4x
P/E RatioIs 4726 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4726 income statement (TTM) | |
---|---|
Revenue | NT$672.85m |
Cost of Revenue | NT$956.07m |
Gross Profit | -NT$283.22m |
Other Expenses | NT$253.11m |
Earnings | -NT$536.33m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -2.60 |
Gross Margin | -42.09% |
Net Profit Margin | -79.71% |
Debt/Equity Ratio | 38.4% |
How did 4726 perform over the long term?
See historical performance and comparison